International Society of Oncology Pharmacy Practitioners
Overall survival was significantly improved by the administration of first-line pertuzumab, trastuzumab and docetaxel in the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) study.
Read more at:
